| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | IN BRIEF: Malin Corp investee signs agreement with Astellas Pharma | 2 | Alliance News | ||
| Di | Earnings call: Astellas Pharma exceeds revenue forecast, faces profit dip | 7 | Investing.com | ||
| 25.04. | Astellas Pharma Annual Net Plunges, But Revenue Climbs; Expects 2024 Result To Improve | 219 | AFX News | TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY), a Japanese pharmaceutical company, on Thursday posted a decline in earnings for the full year, mainly due to higher costs, expenses, and... ► Artikel lesen | |
| 25.04. | Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidance | 9 | Seeking Alpha | ||
| 22.04. | Astellas Pharma Inc.: Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs | 85 | PR Newswire | TOKYO, April 22, 2024 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and... ► Artikel lesen | |
| 26.03. | Astellas Pharma Receives Permanent J-code for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy | 794 | PR Newswire | Permanent J-code J2782 effective April 1, 2024
NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today... ► Artikel lesen | |
| 26.03. | Astellas Pharma Inc.: Astellas' VYLOY (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer | 290 | PR Newswire | VYLOY approved in combination with chemotherapy for patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer
MHLW... ► Artikel lesen | |
| 22.03. | Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting | 305 | AFX News | TOKYO (dpa-AFX) - Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending... ► Artikel lesen | |
| 22.03. | Astellas Pharma Inc.: Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting | 179 | PR Newswire | - If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations... ► Artikel lesen | |
| 04.03. | Astellas Pharma Inc.: Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan | 137 | PR Newswire | TOKYO, March 3, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHT 2 Phase 3 pivotal... ► Artikel lesen | |
| 07.02. | Astellas Pharma Inc.: Astellas Makes Announcement about Management Structure | 474 | PR Newswire | TOKYO, Feb. 6, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its management structure effective April... ► Artikel lesen | |
| 05.02. | Astellas Pharma GAAP EPS of ¥67.20, revenue of ¥1.18B | 15 | Seeking Alpha | ||
| 31.01. | Astellas Pharma Announces Collaboration With Mass General Brigham | 413 | AFX News | TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) said that it has reached a strategic collaboration with Mass General Brigham that is focused on translational medicine and early development... ► Artikel lesen | |
| 26.01. | Astellas Pharma Inc.: European Medicines Agency Validates Type II Variation Application for PADCEV (enfortumab vedotin) with KEYTRUDA(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer | 561 | PR Newswire | - Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival -
- If approved, PADCEV with KEYTRUDA would be the first combination... ► Artikel lesen | |
| 09.01. | Astellas Pharma Inc.: Astellas Provides Update on Zolbetuximab Biologics License Application in U.S. | 399 | PR Newswire | TOKYO, Jan. 8, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) issued a complete... ► Artikel lesen | |
| 28.12.23 | Elpiscience Biopharma, Astellas Pharma Collaborate For Novel Bi-specific Macrophage Engagers | 408 | AFX News | TOKYO (dpa-AFX) - Elpiscience Biopharma, Ltd., a privately held, clinical-stage biopharmaceutical company, and Astellas Pharma Inc. (ALPMY, ALPMY) has entered into a research collaboration and... ► Artikel lesen | |
| 22.12.23 | Astellas Pharma Inc.: Astellas Completes Acquisition of Propella Therapeutics | 352 | PR Newswire | TOKYO, Dec. 21, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today that it has completed the acquisition of Propella Therapeutics... ► Artikel lesen | |
| 11.12.23 | Basilea Pharma: Astellas Pharma Gets FDA Approval For Cresemba's Expanded Use In Kids With IA, IM | 433 | AFX News | LONDON (dpa-AFX) - Switzerland's Basilea Pharmaceutica Ltd. announced Monday that its license partner Astellas Pharma US, Inc. (ALPMY, ALPMY) received the US Food and Drug Administration approval... ► Artikel lesen | |
| 16.11.23 | Astellas Pharma To Buy Propella Therapeutics For About $175 Mln | 831 | AFX News | TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) agreed to buy Propella Therapeutics Inc. for about US$175 million.Propella is a privately held biopharmaceutical company that has leveraged... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 3.760 |
| SUPER MICRO COMPUTER | 2.609 |
| BYD | 2.309 |
| BAYER | 2.234 |
| APPLE | 1.686 |
| NVIDIA | 1.633 |
| NEL | 1.547 |
| DEUTSCHE BANK | 1.396 |
| TUI | 1.393 |
| TESLA | 1.341 |
| AMAZON | 1.078 |
| MERCEDES-BENZ | 1.028 |
| VOLKSWAGEN | 942 |
| COMMERZBANK | 850 |
| PLUG POWER | 839 |
| AIXTRON SE | 821 |
| NOVO NORDISK | 816 |
| PFIZER | 785 |
| RHEINMETALL | 742 |
| HUGO BOSS | 706 |
| PAYPAL | 690 |
| RWE | 686 |
| DEUTSCHE LUFTHANSA | 673 |
| CANOPY GROWTH | 671 |
| BIONTECH | 661 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
